Several activist investors have filed an injunction with the Daejeon District Court in South Korea, demanding that KT&G address their grievances by spinning off its profitable ginseng business, appointing certain external directors, and strengthening its shareholder return policy.
Investor group led by Singaporean private equity firm Flashlight Capital has repeatedly urged the company to spin off its ginseng business to restore the company's value and stock price.
However, during last month's investor relations event, KT&G refused this request. KT&G Senior Executive Vice President Bang Kyung-man stated, "In the long run, splitting the company has almost no benefit for the company's value or shareholders.
Bang expressed concerns that if the ginseng business department separates, KT&G may lose its "synergy".
During the meeting, KT&G rejected a request from the fund to strengthen KT&G's shareholder return policy. The tobacco manufacturer stated that the current policy "should be temporarily retained.
Lee Sang-hyun, the founder of Flashlight Capital, believes that once KT&G adjusts its investment portfolio to better achieve its environmental, social, and governance goals, its stock price will rebound beyond 140,000 Korean won, which was last seen in 2016.
The stock price of KT&G reached its lowest point on February 17 at KRW 87,100, but has since slightly recovered.
Reference:
Investors are urging KT&G to proceed with the spinoff of their ginseng business.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
